Cargando…

Drug-drug interactions between direct-acting antivirals and statins in the treatment of chronic hepatitis C

As the first line of treatment for hepatitis C virus (HCV) infection, direct-acting antivirals (DAAs) have greater efficacy and fewer adverse effects than other treatments; however, drug-drug interactions (DDIs) must be avoided when used in combination with other medications, such as statins. HCV pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuo, Meng-Hsuan, Tseng, Chih-Wei, Lee, Chi-Hui, Tseng, Kuo-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605290/ https://www.ncbi.nlm.nih.gov/pubmed/33163377 http://dx.doi.org/10.4103/tcmj.tcmj_247_19

Ejemplares similares

Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents
por: Chen, Yen-Chun, et al.
Publicado: (2020)

Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy
por: Chen, Yen-Chun, et al.
Publicado: (2021)

Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals
por: Chen, Yen-Chun, et al.
Publicado: (2021)

Direct-Acting Antiviral Drugs Reduce Fibromyalgia Symptoms in Patients with Chronic Hepatitis C
por: Tang, Kuo-Tung, et al.
Publicado: (2022)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Drug–Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C
por: Gao, Lu-Hua, et al.
Publicado: (2021)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
por: Chen, Yen-Chun, et al.
Publicado: (2022)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C
por: Lin, Sheng Feng, et al.
Publicado: (2020)

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
por: Chen, Chi‐Yi, et al.
Publicado: (2021)

Drug-drug interactions with direct-acting antivirals — less is more
por: Wong, Grace Lai-Hung
Publicado: (2021)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
por: Hong, Jenny, et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
por: Smolders, E. J., et al.
Publicado: (2016)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment
por: Kuo, Meng Hsuan, et al.
Publicado: (2021)

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
por: Canonico, Mario Enrico, et al.
Publicado: (2022)

Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
por: Bellesini, Marta, et al.
Publicado: (2020)

Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case Report
por: Hsiao, Chien-Hao, et al.
Publicado: (2015)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
por: Hsu, Jui-Ting, et al.
Publicado: (2022)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
por: Alian, Samah M., et al.
Publicado: (2020)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
por: Hawsawi, Nahed Mohammed, et al.
Publicado: (2023)

Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting
por: Koustenis, Kanellos Rafail, et al.
Publicado: (2020)

Real-world efficacy and safety of direct-acting antiviral drugs in patients with chronic hepatitis C and inherited blood disorders
por: Ruiz, Isaac, et al.
Publicado: (2021)

In a Real-Life Setting, Direct-Acting Antivirals to People Who Inject Drugs with Chronic Hepatitis C in Turkey
por: Sarıgül Yıldırım, Figen, et al.
Publicado: (2022)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Current therapy for chronic hepatitis C: The role of direct-acting antivirals
por: Li, Guangdi, et al.
Publicado: (2017)

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
por: Zeng, Haiyan, et al.
Publicado: (2020)

The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma
por: Chen, Yu-Syuan, et al.
Publicado: (2022)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
por: Mada, Pradeep Kumar, et al.
Publicado: (2020)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
por: Cárdaba-García, María E., et al.
Publicado: (2021)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
por: Izhari, Mohammad Asrar
Publicado: (2023)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection
por: Kanda, Tatsuo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kfmktju98i1gilmc81vdaullip